Search Results

Edenbridge Pharmaceuticals, the U.S. subsidiary of Dexcel Pharma, announced that Douglas S. Boothe has been named Chief Executive Officer, effective January 1, 2024.

PANTHERx®Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Edenbridge Pharmaceuticals for the distribution of Yargesa® (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.

Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, the commercialization partner and eHub for DARTISLA ODT, as well as in retail pharmacies throughout the country.

Edenbridge’s first 505(b)(2) branded drug to be granted FDA approval.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.